Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern
about
Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particleResistance to anti-influenza drugs: adamantanes and neuraminidase inhibitorsAmantadine and rimantadine for influenza A in children and the elderlyAmantadine and rimantadine for influenza A in children and the elderlyCurrent and future antiviral therapy of severe seasonal and avian influenzaCurrent Approaches for Diagnosis of Influenza Virus Infections in HumansViral-bacterial interactions-therapeutic implicationsInfluenza treatment and prophylaxis with neuraminidase inhibitors: a reviewSafety and efficacy of peramivir for influenza treatmentDiscovery of Influenza A Virus Sequence Pairs and Their Combinations for Simultaneous Heterosubtypic Targeting that Hedge against Antiviral ResistanceBroad-Spectrum Drugs Against Viral AgentsRNA virus genomics: a world of possibilitiesStructural basis for the function and inhibition of an influenza virus proton channelStructure of Amantadine-Bound M2 Transmembrane Peptide of Influenza A in Lipid Bilayers from Magic-Angle-Spinning Solid-State NMR: The Role of Ser31 in Amantadine BindingSolution NMR structure of the V27A drug resistant mutant of influenza A M2 channelThe management of acute bronchitis in childrenEfficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza virusesHost modulators of H1N1 cytopathogenicityAmino acids transitioning of 2009 H1N1pdm in Taiwan from 2009 to 2011Inhibitors of the influenza A virus M2 proton channel discovered using a high-throughput yeast growth restoration assayEfficacy of influenza vaccination and tamifluĀ® treatment--comparative studies with Eurasian Swine influenza viruses in pigsSimultaneous detection of oseltamivir- and amantadine-resistant influenza by oligonucleotide microarray visualizationEpidemiological and virological characteristics of influenza viruses circulating in Cambodia from 2009 to 2011Assessment of the antiviral properties of recombinant porcine SP-D against various influenza A viruses in vitroInfluenza virus non-structural protein 1 (NS1) disrupts interferon signalingPrevention and treatment of influenza with hyperimmune bovine colostrum antibodyPostviral Complications: Bacterial PneumoniaNeuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children.Pandemic and seasonal influenza: therapeutic challengesDrug resistance in influenza A virus: the epidemiology and management.Investigational hemagglutinin-targeted influenza virus inhibitors.Emergence of drug-resistant influenza virus: population dynamical considerations.Antiviral management of seasonal and pandemic influenza.Role of combination antiviral therapy in pandemic influenza and stockpiling implications.The threat of avian influenza H5N1: 'do we have the tools for the job'?Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact.Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo.Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo.The role of oseltamivir in the treatment and prevention of influenza in children.Phenyl substituted 4-hydroxypyridazin-3(2H)-ones and 5-hydroxypyrimidin-4(3H)-ones: inhibitors of influenza A endonuclease.
P2860
Q21562299-4A84A19A-E3E2-491C-A86D-333D01CF2B30Q22305941-98DEC001-EB6E-48A7-A0A9-55AB9BE69115Q24187883-32203774-C03A-4AD4-952A-60DD88DDECCBQ24203853-D3710C43-F44C-4C00-A593-2C302870D231Q24656164-CAF08380-1DAE-4450-80A5-C7724F855918Q26748397-795C5A44-CEA7-4A62-B678-1529F3F73C18Q26825261-9F70814A-B042-47E1-8E1B-ED50395F145BQ26860032-54A0F74D-0721-493D-959E-6123B4C066DEQ27027408-68B170AC-D4E2-4E2C-AC0F-AB6C6BEAD9B9Q27316994-79145326-2C0D-4607-8076-63BFD6544F6FQ27487859-1449DC2F-706F-4E30-B5E2-9198732B4BC2Q27489430-4CDC8DD4-A7AF-43BD-AA74-931243725F09Q27649742-907ECB6A-EED8-4A7A-A0B7-46D8A065AA69Q27653082-A2B1F311-B397-400A-93ED-92CA60734AFBQ27664419-700EE7EC-BB92-4EBC-BC2E-BD56FB44FF5AQ28288887-6FFA76B5-42B5-4E6F-B3F1-15EDC458FA7DQ28473051-5AF17FE4-C490-42FF-80E2-97229D6BEFBDQ28481798-216E40A8-13EA-47F4-86EF-2C9D9E8C99A9Q28483965-3C5639DA-2ABF-499E-AD61-F458123FBFB6Q28485914-A5BC2B83-4832-444E-B494-1ED0BD049492Q28486415-AF1C286D-9388-4652-8D28-7F088D740BEBQ28486551-7C9B208A-2E57-439F-984D-B38B1EF61BF9Q28544035-A1CDD6A7-0274-4C19-9EE6-80F2CA01D2B7Q28740380-A7AC2C56-8766-4805-B57E-9886627AB222Q28748500-594EAB9B-BC1C-4814-92AE-062AD7B38014Q28748705-CEED705A-4C50-4704-A4E0-1CCA2F2938BAQ29248089-7DD97F2C-84A1-49C5-90BF-A63DE0A18C1CQ30228322-A444FAD3-4F5B-4EA1-9445-85764AB37F6DQ30228856-20B420F8-752B-4961-ACE3-F834BD7AB086Q30234600-B8626A44-CB8F-44BA-AA70-6B5F8CE84B43Q30240175-86F8DA68-E082-437E-9DE7-6B92733E0555Q30353989-D59E92DC-122A-499E-BD8D-70E850AE422BQ30358735-7DE5BD56-AAF1-401D-BEFC-87719F5CB733Q30359766-CD577024-68AF-4712-BA2C-2001D5EE5837Q30362060-6C7EE0D3-9A12-4811-8B64-062483219258Q30362700-6E5297BE-1ACB-4337-B152-EED535FAD645Q30363986-76584263-9361-4F0A-B438-C6FA970E6514Q30364619-EEA5CD14-27DA-4D94-B789-707BB1497B35Q30364977-B4761098-3FFE-4F93-BEAE-F1E11510F45AQ30366846-F18E482F-9D8E-4D2E-BBF7-068E03FC34DB
P2860
Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern
description
2005 nĆ® lÅ«n-bĆ»n
@nan
2005 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« ÕÕøÕÆÕæÕ„Õ“Õ¢Õ„ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2005 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Õ°ÕøÕæÕ„Õ“Õ¢Õ„ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2005幓ć®č«ę
@ja
2005幓č«ę
@yue
2005幓č«ę
@zh-hant
2005幓č«ę
@zh-hk
2005幓č«ę
@zh-mo
2005幓č«ę
@zh-tw
2005幓č®ŗę
@wuu
name
Incidence of adamantane resist ...... 4 to 2005: a cause for concern
@ast
Incidence of adamantane resist ...... 4 to 2005: a cause for concern
@en
Incidence of adamantane resist ...... 4 to 2005: a cause for concern
@nl
type
label
Incidence of adamantane resist ...... 4 to 2005: a cause for concern
@ast
Incidence of adamantane resist ...... 4 to 2005: a cause for concern
@en
Incidence of adamantane resist ...... 4 to 2005: a cause for concern
@nl
prefLabel
Incidence of adamantane resist ...... 4 to 2005: a cause for concern
@ast
Incidence of adamantane resist ...... 4 to 2005: a cause for concern
@en
Incidence of adamantane resist ...... 4 to 2005: a cause for concern
@nl
P2093
P3181
P1433
P1476
Incidence of adamantane resist ...... 4 to 2005: a cause for concern
@en
P2093
Alexander I Klimov
Gilda Perez-Oronoz
Laura Povinelli
Marie-jo Medina
Nancy J Cox
Teresa R Wallis
Xiaohong M Davis
P304
P3181
P356
10.1016/S0140-6736(05)67338-2
P407
P50
P577
2005-10-01T00:00:00Z